secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fresh Tracks Therapeutics, Inc. (—)
CIK:        0000819050
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001628280-23-034176
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Sklawer departs; severance includes $441K lump sum, full equity vesting, $425/hr consulting
--------------------------------------------------------------------------------

- CEO Andrew Sklawer terminated without cause effective Oct 2, 2023; severance of $441k (12 months base) plus $44k retention bonus.
- Accrued PTO paid $165,375; health care premiums for 12 months with 35% gross-up if continued coverage not available.
- All unvested equity awards fully vested as of Separation Date; equity exercise extended to 3 years.
- Sklawer to provide consulting via Yonder Partners at $425 per hour; contract terminable by either party.
- CEO departure in connection with previously disclosed plan to liquidate and dissolve the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/819050/000162828023034176/0001628280-23-034176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/819050/000162828023034176/frtx-20231003.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-034176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer